Encouraging Report, page-68

You could apply same arguments to your Resonance Health.... uptake of technology is excruciatingly slow and glacial...

With microcaps I would rather stick with "ticket-clipping" business models before getting into brand ownership. Ticket clipping leverages you into the upside at zero cost if the licensee expands business.

What we do know:

* ramp up has been slow, not due to demand but due to supply
* the company has been provided a sales/revenue plan out to 2021
* P&G has/is expanding Magnemask from China/Taiwan/Phillipines/USA/Australia. Thats expansion, not contraction.
* P&G have signed up to a second technology thats being consumer tested. Thats expansion not contraction of interest
* P&G have given back other technologies. No great surprise as P&G is made up of silos and our technology might interest some but not all stakeholders.

As for the non-ticket clipping business, what we do know is:

* stakeholders werent interested in BodyGuard until a commercial ready product was available. That became available in November 2017
* a UK company is funding and running a consumer and efficacy trial right now - something that didnt happen when you held I presume.
* a second trial of Surface Hygiene is occurring.

Salty Stale Bulls might call it continued carrot dangling, I call it things that are very much still in play...